Case series shows upadacitinib controls IBD in 2 of 4 patients after liver transplantation, suggesting careful monitoring due to liver enzyme elevations.
Key Points
This case series aims to evaluate the efficacy and safety of upadacitinib in patients with inflammatory bowel disease after liver transplantation.
Retrospective, single-center observational study
Identified patients after liver transplantation who received upadacitinib
Assessed efficacy and safety outcomes
Two of four patients achieved control of inflammatory bowel disease activity with upadacitinib
Three patients experienced liver enzyme elevation related to treatment
No life-threatening adverse events occurred during the follow-up period